Physician profile

Jonathan A Bradlow

Cardiovascular Disease · Bronx, NY

NPI 1013014836

$114,334.31

in general payments reported to CMS, 2019-2025

40 companies · $3,256 in 2025

The $3,256 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$7,848.56
Consulting Fee$2,212.50
Education$9.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $52,300.23 2019-2025 Jardiance
Astrazeneca Pharmaceuticals LP $20,684.69 2020-2025 Farxiga, Brilinta, Lokelma
Medtronic, INC. $10,603.41 2021-2023 Corevalve Evolut R
Lilly USA, LLC $7,060.41 2019-2024 Mounjaro
Gilead Sciences, INC. $6,513.78 2021-2022
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $3,926.00 2019-2025 Lifevest
Boston Scientific Corporation $2,462.07 2019-2025 Watchman Flx
Medtronic Vascular, INC. $1,603.37 2019-2020
Amgen INC. $1,071.09 2019-2025 Repatha, Repatha
Pfizer INC. $985.66 2019-2025
Novartis Pharmaceuticals Corporation $950.99 2019-2025
E.R. Squibb & Sons, L.L.C. $904.49 2020-2025 Eliquis, Camzyos
Merck Sharp & Dohme LLC $799.79 2021-2025 Verquvo
Analog Devices INC. $525.00 2025
Abbott Laboratories $512.98 2021-2025 Mitraclip, Jot Dx
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Alnylam Pharmaceuticals INC. $389.71 2022-2025 Onpattro, Amvuttra
Esperion Therapeutics, INC. $383.89 2024-2025 Nexletol
Novo Nordisk INC $358.82 2021-2025 Ozempic, Wegovy, Rybelsus
Janssen Scientific Affairs, LLC $280.48 2023-2024 Xarelto
Kiniksa Pharmaceuticals International, Plc $276.45 2024 Arcalyst
Bridgebio Pharma, INC. $255.38 2025 Attruby
Janssen Pharmaceuticals, INC $204.13 2019-2024 Xarelto
Sanofi-Aventis U.S. LLC $167.09 2022-2023
Regeneron Healthcare Solutions, INC. $157.51 2019
Abiomed $153.76 2025
Lexicon Pharmaceuticals, INC. $133.65 2023-2024 Inpefa
Baxter Healthcare $98.85 2022
Scpharmaceuticals INC. $92.07 2024-2025
Agepha Pharma Fz LLC $90.37 2025 Lodoco
Vifor Pharma, INC. $57.14 2020-2021
Celgene Corporation $46.35 2024-2025 Camzyos
Biotronik INC. $45.01 2019
Amarin Pharma, INC. $39.12 2022
Althera Pharmaceuticals LLC $38.74 2021-2022
Philips North America LLC $35.79 2023-2024 (5046) Holter
Kowa Pharmaceuticals America, INC. $29.71 2020-2021
Impulse Dynamics (USA) INC. $25.64 2023 Optimizer
Bayer Healthcare Pharmaceuticals INC. $24.58 2022
Portola Pharmaceuticals, LLC $23.78 2019
Kiniksa Pharmaceuticals, LTD. $22.33 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$375.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan A Bradlow

$114,334.31

in general payments reported 2019-2025

Years
2019-2025
Top company
Boehringer Ingelheim Pharmaceuticals, INC.
Context
The $3,256 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/317930/jonathan-a-bradlow

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.